ScholarIQanswers from OpenAlex

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

PaperCitations, authors & open-access status

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment have?

ScholarIQcitation count

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment has 64 citations in the OpenAlex counts ScholarIQ stores.

When was Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment published?

ScholarIQyear

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment has 2021 year in the ScholarIQ index.

What is the open-access status of Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment?

ScholarIQoa status

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment has gold oa status in the ScholarIQ index.

What is the DOI of Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment?

ScholarIQdoi

The DOI for Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment is on the source record.

What is the PMID of Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment?

ScholarIQpmid

The PMID for Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment is on the source record.

What is the OpenAlex record for Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment?

ScholarIQopenalex

The OpenAlex for Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial